BRAF and metastatic colorectal cancer: In metastatic colorectal cancer (mCRC), KRAS, NRAS, and BRAF assessment is mandatory for treatment selection and prognostication, as RAS mutations confer resistance to anti-EGFR antibodies and BRAF V600 mutations indicate poor prognosis.